OrbiMed Invests $8 Million In Response Biomedical To Reap Rewards Of China's Rapid Growth POCT Market
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Life sciences and health investment firm OrbiMed recently injected $8 million in Response Biomedical, a Vancouver-based company providing rapid test products based on its RAMP platform and targeting the rapid growth of China's point-of-care testing market
You may also be interested in...
With Investment In Bharat Serum, OrbiMed Speeds Up Its Second Deal In India In Four Months
MUMBAI - The world's largest healthcare fund OrbiMed seems to be in a hurry to invest in emerging Indian companies. Less than four months after the nearly $5 billion fund made its debut with investments in the Southern Indian clinical research outfit Ecron Acunova, it has now struck its second deal with Bharat Serums and Vaccines - a mid-sized biopharmaceutical unit that mainly manufactures niche life-saving injectable drugs
Global VC OrbiMed Leads Series A Financing In Its Second China Start-up Investment
SHANGHAI - Life sciences and health investment firm OrbiMed announced March 8 that it has led $6.6 million series A financing for Chinese dental company EA Inc., which is focusing on providing invisible orthodontic braces to China's rising middle class
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).